Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Epistemonikos ID: 6932862a4f7b27035bbbd2de69ea1a3e1a033706
First added on: Oct 03, 2025